Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Resistant AP/BP CML
NCT00449761Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of panobinostat in chronic myeloid leukemia (CML), sponsored by Novartis. Started Feb 2007; status: terminated.
02
Drugs
panobinostat
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00449761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00449761.